VioQuest Pharmaceuticals, Inc. (VOQP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2007 | 2.93 Million USD | 1007.38% |
| 2006 | 264.62 Thousand USD | 0.0% |
| 2005 | 264.62 Thousand USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 80.62 Thousand USD | 13.94% |
| 2000 | 70.76 Thousand USD | 23.72% |
| 1999 | 57.19 Thousand USD | 0.0% |
| 1998 | 57.19 Thousand USD | -5.19% |
| 1997 | 60.32 Thousand USD | -4.99% |
| 1996 | 63.48 Thousand USD | -16.79% |
| 1995 | 76.29 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2008 Q1 | - USD | -100.0% |
| 2008 Q2 | - USD | 0.0% |
| 2007 Q2 | 1.95 Million USD | 98.26% |
| 2007 Q3 | 2.55 Million USD | 30.7% |
| 2007 Q4 | 2.93 Million USD | 14.89% |
| 2007 Q1 | 984.3 Thousand USD | 271.96% |
| 2007 FY | 2.93 Million USD | 1007.38% |
| 2006 FY | 264.62 Thousand USD | 0.0% |
| 2006 Q1 | 264.62 Thousand USD | 0.0% |
| 2006 Q2 | 264.62 Thousand USD | 0.0% |
| 2006 Q3 | 264.62 Thousand USD | 0.0% |
| 2006 Q4 | 264.62 Thousand USD | 0.0% |
| 2005 Q4 | 264.62 Thousand USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | 264.62 Thousand USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 FY | - USD | -100.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q2 | - USD | -100.0% |
| 2002 Q1 | 20 Thousand USD | -75.19% |
| 2001 Q2 | 62.97 Thousand USD | -9.59% |
| 2001 Q3 | 61.81 Thousand USD | -1.84% |
| 2001 Q4 | 80.62 Thousand USD | 30.44% |
| 2001 FY | 80.62 Thousand USD | 13.94% |
| 2001 Q1 | 69.65 Thousand USD | -1.57% |
| 2000 Q4 | 70.76 Thousand USD | -1.49% |
| 2000 Q3 | 71.82 Thousand USD | -1.47% |
| 2000 FY | 70.76 Thousand USD | 23.72% |
| 2000 Q1 | 75.46 Thousand USD | 0.0% |
| 2000 Q2 | 72.89 Thousand USD | -3.41% |
| 1999 FY | 57.19 Thousand USD | 0.0% |
| 1998 FY | 57.19 Thousand USD | -5.19% |
| 1997 FY | 60.32 Thousand USD | -4.99% |
| 1996 FY | 63.48 Thousand USD | -16.79% |
| 1995 FY | 76.29 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 92.888% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 28.908% |
| SQZ Biotechnologies Company | 27.47 Million USD | 89.333% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 93.244% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 90.156% |
| Mesoblast Limited | 118.7 Million USD | 97.531% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -209.024% |
| Genus plc | 233.1 Million USD | 98.743% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -118.102% |
| Marizyme, Inc. | 18.71 Million USD | 84.344% |
| ContraFect Corporation | 2.88 Million USD | -1.714% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -290.718% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2062.855% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -102.61% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -25.986% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 48.211% |
| MultiCell Technologies, Inc. | 202.58 USD | -1446433.715% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 94.903% |
| EV Biologics, Inc. | 1.49 Million USD | -96.045% |
| Q BioMed Inc. | 4.1 Million USD | 28.701% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 91.147% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -365.084% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -138.561% |
| Biomind Labs Inc. | 735.54 Thousand USD | -298.398% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 98.292% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 77.453% |
| Skye Bioscience, Inc. | 4.61 Million USD | 36.507% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -229.975% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1970.682% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 50.088% |
| IMV Inc. | 28.88 Million USD | 89.855% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -11293.864% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -29.756% |
| GB Sciences, Inc. | 1.75 Million USD | -66.565% |
| Alpha Cognition Inc. | 1.22 Million USD | -140.123% |
| HST Global, Inc. | 98.31 Thousand USD | -2880.49% |
| CSL Limited | 12.18 Billion USD | 99.976% |
| Halberd Corporation | 150 Thousand USD | -1853.592% |
| Enzolytics Inc. | 996.33 Thousand USD | -194.116% |
| Resverlogix Corp. | 6.49 Million USD | 54.855% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -513.694% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1046.51% |
| argenx SE | 20 Million USD | 85.348% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 93.568% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -8.184% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -28559.051% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.299% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1360.695% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -22.215% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1178.021% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 95.668% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 3.166% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -714.653% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 85.584% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1871.281% |
| BioStem Technologies, Inc. | 4.71 Million USD | 37.802% |
| ONE Bio Corp. | 19.71 Million USD | 85.136% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1071.302% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1078.188% |
| Agentix Corp. | 50 Thousand USD | -5760.776% |
| LadRx Corporation | 33.6 Thousand USD | -8619.836% |
| Cell Source, Inc. | 9.25 Million USD | 68.334% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -287.513% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -287.513% |
| NovAccess Global Inc. | 2.19 Million USD | -33.207% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 58.568% |
| Itoco Inc. | 228.37 Thousand USD | -1183.136% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1288.974% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 41.192% |
| Kadimastem Ltd | 891.22 Thousand USD | -228.804% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -629.226% |
| CytoDyn Inc. | 30.07 Million USD | 90.257% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -505.097% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -732.859% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 62.527% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -2292.153% |
| Rebus Holdings, Inc. | 310 Thousand USD | -845.286% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 38.116% |
| International Stem Cell Corporation | 4.17 Million USD | 29.861% |
| Bioxytran, Inc. | 1.92 Million USD | -52.228% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -4595.156% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -34.366% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 64.762% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 65.866% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -88.391% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -993.428% |
| Neutra Corp. | 54.15 Thousand USD | -5311.013% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -60.13% |
| PureTech Health plc | 25.51 Million USD | 88.514% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -139.367% |
| IXICO plc | 472.02 Thousand USD | -520.815% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 81.095% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 95.294% |
| CSL Limited | 12.18 Billion USD | 99.976% |
| Cellectis S.A. | 92.77 Million USD | 96.841% |